New data show AAV-delivered antibody fragments targeting oxidized phosphatidylcholines (PC-OxPL), a species of oxidized phospholipids, thereby neutralizing ...

Golden said painless progressive weakness is the key to recognizing ALS, and although research still has a long way to go, ...

Coya Therapeutics, Inc.’s COYA share price has surged by 12.31%, which has investors questioning if this is right time to ...

A groundbreaking achievement in brain-computer interface technology: an ALS patient uses a Neuralink implant to edit and narrate a YouTube video.

The third patient of Elon Musk's brain computer interface company Neuralink is using Musk's AI chatbot Grok to speed up ...

Smith is the first non-verbal individual and only the third person globally to receive a Neuralink Brain-Chip Interface (BCI) implant.

The approved ALS therapy Radicava may cause serious unexpected side effects, such as liver problems and blood clots, per U.S.

Clene’s cash and cash equivalents totaled $9.8 million as of March 31, 2025, compared to $12.2 million as of December 31, 2024. Clene expects that its resources as of March 31, 2025, will be ...

Prilenia, Ferrer entered collaboration agreement for commercialization and co-development of pridopidine in Europe and other ...

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

Houston mortgage duo Cissy and Christopher Larkin are channeling a four-year ALS battle into a widespread fundraiser.